Citation: | Xiaoyu Liu, Huihan Wang. Efficacy of E-COD regimen in the treatment of HHV-8 negative multicentric Castleman disease[J]. Blood&Genomics. doi: 10.46701/BG.2023012022037 |
[1] |
Yu L, Shi M, Cai Q, et al. A novel predictive model for idiopathic multicentric Castleman disease: the internatiman disease consortium study[J]. Oncologist, 2020, 25(11): 963−973. doi: 10.1634/theoncologist.2019-0986
|
[2] |
van Rhee F, Oksenhendler E, Srkalovic G, et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease[J]. Blood Adv, 2020, 4(23): 6039−6050. doi: 10.1182/bloodadvances.2020003334
|
[3] |
van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease[J]. Blood, 2018, 132(20): 2115−2124. doi: 10.1182/blood-2018-07-862334
|
[4] |
Frizzera G. Castleman's disease and related disorders[J]. Semin Diagn Pathol, 1988, 5(4): 346−364
|
[5] |
Zhang X, Rao H, Xu X, et al. Clinical characteristics and outcomes of Castleman disease: a multicenter study of 185 Chinese patients[J]. Cancer Sci, 2018, 109(1): 199−206. doi: 10.1111/cas.13439
|
[6] |
Dong Y, Wang M, Nong L, et al. Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor[J]. Br J Haematol, 2015, 169(6): 834−842. doi: 10.1111/bjh.13378
|
[7] |
Yu L, Tu M, Cortes J, et al. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease[J]. Blood, 2017, 129(12): 1658−1668. doi: 10.1182/blood-2016-11-748855
|
[8] |
Zhang L, Zhao AL, Duan MH, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease[J]. Blood, 2019, 133(16): 1720−1728. doi: 10.1182/blood-2018-11-884577
|
[9] |
Zou WY, Lan HX, Su C, et, al. Retrospective study of Castleman's disease: a report of fourteen cases and review of the literature[J]. Chin J Clin Oncol (in Chinese), 2007, 34(22): 195−200.
|
[10] |
Murphy C, Hawkes E, Chionh F, et al. Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab, and liposomal doxorubicin in an HHV8-positive, HIV-negative patient[J]. J Clin Pharm Ther, 2017, 42(1): 111−114. doi: 10.1111/jcpt.12472
|
[11] |
Dispenzieri A. Castleman disease[J]. Cancer Treat Res, 2008, 142: 293−330. doi: 10.1007/978-0-387-73744-7_13
|
[12] |
van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease: a randomised, double- blind, placebo controlled trial[J]. Lancet Oncol, 2014, 15(9): 966−974. doi: 10.1016/S1470-2045(14)70319-5
|
[13] |
Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment[J]. Blood, 2004, 103(5): 163−634. doi: 10.1182/blood-2003-05-1721
|
[14] |
Song Y, Wang J, Wang Y, et al. Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis[J]. Cancer Biol Ther, 2021, 22(10–12): 598−606. doi: 10.1080/15384047.2021.1996139
|
[15] |
Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease[J]. Blood, 2020, 135(16): 1353−1364. doi: 10.1182/blood.2019000931
|
[16] |
Zhang L, Li Z, Cao X, et al. Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman's disease: renal function is an important prognostic factor[J]. Sci Rep, 2016, 6: 23831. doi: 10.1038/srep23831
|
[17] |
Joel SP, Shah R, Slevin ML. Etoposide dosage and pharmacodynamics[J]. Cancer Chemother Pharmacol, 1994, 34: Suppl: S69−75. doi: 10.1007/BF00684867
|